Table 3.
Analytical Results for Isoprostanes, Isofurans, Neuroprostanes, and Neurofurans Determined in Urine of Preterm Infants ≤32 Weeks of Gestation by Ultra-Performance Liquid Chromatography–Tandem Mass Spectrometry
| Postnatal day 1 | Postnatal day 3 | Postnatal day 4 | Postnatal day 6 | Postnatal day 7 | Postnatal day 14 | Postnatal day 21 | Postnatal day 28 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Control (95) | BPD (22) | Control (126) | BPD (24) | Control (93) | BPD (25) | Control (86) | BPD (18) | Control (19) | BPD (18) | Control (33) | BPD (23) | Control (26) | BPD (15) | Control (48) | BPD (28) | |
| IsoPs | 494 (926) | 534 (354) | 1016 (1391) | 955 (567) | 1201 (1370) | 1339 (1012) | 802 (1074) | 998 (562) | 154 (208) | 194 (155) | 81 (85) | 102 (66) | 75 (53) | 96 (77) | 152 (402) | 177 (234) |
| IsoFs | 211 (239) | 445 (188)a | 507 (413) | 788 (374)a | 844 (590) | 1233 (667)b | 807 (535) | 944 (667) | 547 (651) | 612 (548) | 292 (372) | 334 (185) | 225 (215) | 198 (155) | 167 (188) | 198 (219) |
| NeuroPs | 37 (61) | 46 (51) | 32 (34) | 58 (42) | 37 (65) | 58 (44) | 39 (27) | 52 (33) | 19 (18) | 25 (14) | 166 (291) | 192 (144) | 332 (356) | 379 (224) | 213 (290) | 254 (310) |
| NeuroFs | 14 (26) | 20 (18) | 24 (26) | 39 (18) | 28 (21) | 38 (31) | 29 (24) | 25 (21) | 44 (38) | 54 (44) | 39 (39) | 51 (44) | 50 (48) | 43 (38) | 23 (28) | 34 (19) |
Results of preterm infants who did not develop free radical-associated conditions (controls) are compared with patients who developed BPD defined as need of oxygen supplementation at 36 weeks postconceptional age. Results are expressed as intensity of signal units/ml of urine and expressed as mean (standard deviation).
a
Significance: p<0.01
b
Significance: p<0.05.
IsoFs, isofurans; IsoPs, isoprostanes; NeuroFs, neurofurans; NeuroPs, neuroprostanes.